- Report
- November 2023
- 140 Pages
Global
From €2416EUR$2,499USD£2,076GBP
- Report
- April 2024
- 180 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- October 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- October 2023
- 172 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- December 2023
- 171 Pages
Global
From €3512EUR$3,633USD£3,019GBP
€5017EUR$5,190USD£4,312GBP
- Report
- February 2024
- 110 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Drug Pipelines
- April 2024
- 100 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1208EUR$1,250USD£1,039GBP
- Report
- November 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- October 2023
- 181 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- June 2023
- 113 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- February 2024
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 111 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 112 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- November 2023
- 110 Pages
Global
From €4350EUR$4,500USD£3,739GBP
The Hospital Acquired Infection (HAI) market is a subset of the Infectious Diseases Drugs market. HAIs are infections that occur in a hospital setting, and can be caused by a variety of bacteria, viruses, and fungi. These infections can be difficult to treat, as they are often resistant to antibiotics. As such, HAI drugs are designed to target specific pathogens, and are often used in combination with other treatments.
The HAI market is driven by the increasing prevalence of antibiotic-resistant infections, as well as the need for more effective treatments. Additionally, the rising number of hospitalizations due to chronic illnesses has also contributed to the growth of the market.
Some of the major players in the HAI market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, and Johnson & Johnson. These companies are actively developing new drugs and treatments to address the growing prevalence of HAIs. Show Less Read more